The past and future of ‘reported outcomes’ in studies on chemotherapy neuropathy

The manuscript by Park et al. in this issue of Annals of Oncology [1] reports on potential clinical and genetic prognostic factors of chemotherapy-induced peripheral neuropathy (CIPN). Predicting CIPN in individual patients, before symptoms manifest, is a critical goal that has not been achieved in the field. Even at the cohort level (a lesser challenge) available CIPN studies tend to disagree, regarding which predictors (genetic and otherwise) are significant. Therefore, additional clinical data are critically needed. We congratulate Park et al. on achieving this step: to put ICON7, a large, high-quality clinical trial, onto the 'map' of CIPN research.